Nasdaq:US$17.45 (-0.03) | HKEX:HK$26.80 (-0.58) | AIM:£2.55 (-0.09)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China, striving to create differentiated novel oncology and immunology treatments with potential to be marketed globally.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.